Literature DB >> 27493307

Classic ataxia-telangiectasia in a Sudanese boy: Case report and review of the literature.

Haydar El Hadi Babikir1.   

Abstract

Ataxia-telangiectasia (A-T) is a rare hereditary neurodegenerative disorder. Ataxia and telangiectasias are the hallmarks of the disease. A spectrum of manifestations may be seen in one family. There is no gold standard diagnostic test and diagnosis relies on clinical evaluation, exclusion of similar conditions, and supportive laboratory tests. More than 99% of individuals with classic A-T have mutations in ATM, the only gene known to be associated with ataxia-telangiectasia. We report a 28-months-old Sudanese boy who was presented with unsteady gait, frequent falls and telangectasias of the eyes. He also has had frequent episodes of respiratory tract infections.

Entities:  

Keywords:  Ataxia-telangectasia; Child; Immuno-deficiency; Sudan

Year:  2011        PMID: 27493307      PMCID: PMC4949784     

Source DB:  PubMed          Journal:  Sudan J Paediatr        ISSN: 0256-4408


  11 in total

1.  Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection.

Authors:  E BODER; R P SEDGWICK
Journal:  Pediatrics       Date:  1958-04       Impact factor: 7.124

2.  Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity.

Authors:  A M Taylor; D G Harnden; C F Arlett; S A Harcourt; A R Lehmann; S Stevens; B A Bridges
Journal:  Nature       Date:  1975-12-04       Impact factor: 49.962

Review 3.  The role of ATM in DNA damage responses and cancer.

Authors:  C E Canman; D S Lim
Journal:  Oncogene       Date:  1998-12-24       Impact factor: 9.867

4.  Ataxia-Telangiectasia: a multiparameter analysis of eight families.

Authors:  R A Gatti; M Bick; C F Tam; M A Medici; V A Oxelius; M Holland; A L Goldstein; E Boder
Journal:  Clin Immunol Immunopathol       Date:  1982-05

5.  Epstein-Barr virus-transformed lymphoblastoid cell lines of ataxia telangiectasia patients are defective in X-ray-induced apoptosis.

Authors:  A E Meijer; B Zhivotovsky; R Lewensohn
Journal:  Int J Radiat Biol       Date:  1999-06       Impact factor: 2.694

6.  Identification and functional consequences of a novel MRE11 mutation affecting 10 Saudi Arabian patients with the ataxia telangiectasia-like disorder.

Authors:  Marie Fernet; Moez Gribaa; Mustafa A M Salih; Mohamed Zein Seidahmed; Janet Hall; Michel Koenig
Journal:  Hum Mol Genet       Date:  2004-12-01       Impact factor: 6.150

7.  Clinical and molecular characterization of ataxia with oculomotor apraxia patients in Saudi Arabia.

Authors:  Saeed A Bohlega; Jameela M Shinwari; Latifa J Al Sharif; Dania S Khalil; Thamer S Alkhairallah; Nada A Al Tassan
Journal:  BMC Med Genet       Date:  2011-02-16       Impact factor: 2.103

8.  Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients.

Authors:  M Anheim; B Monga; M Fleury; P Charles; C Barbot; M Salih; J P Delaunoy; M Fritsch; L Arning; M Synofzik; L Schöls; J Sequeiros; C Goizet; C Marelli; I Le Ber; J Koht; J Gazulla; J De Bleecker; M Mukhtar; N Drouot; L Ali-Pacha; T Benhassine; M Chbicheb; A M'Zahem; A Hamri; B Chabrol; J Pouget; R Murphy; M Watanabe; P Coutinho; M Tazir; A Durr; A Brice; C Tranchant; M Koenig
Journal:  Brain       Date:  2009-08-20       Impact factor: 13.501

9.  Assessment of carriers' frequency of a novel MRE11 mutation responsible for the rare ataxia telangiectasia-like disorder.

Authors:  Ghazi Alsbeih; Khaled Al-Hadyan; Najla Al-Harbi
Journal:  Genet Test       Date:  2008-09

10.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase.

Authors:  K Savitsky; A Bar-Shira; S Gilad; G Rotman; Y Ziv; L Vanagaite; D A Tagle; S Smith; T Uziel; S Sfez; M Ashkenazi; I Pecker; M Frydman; R Harnik; S R Patanjali; A Simmons; G A Clines; A Sartiel; R A Gatti; L Chessa; O Sanal; M F Lavin; N G Jaspers; A M Taylor; C F Arlett; T Miki; S M Weissman; M Lovett; F S Collins; Y Shiloh
Journal:  Science       Date:  1995-06-23       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.